Project Details
Project Description
| Status | Active |
|---|---|
| Effective start/end date | 25/07/23 → 24/07/28 |
Clinical Trial Phase
- Phase I
- Phase II
An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory autoimmune disorders
- Gregory, Gareth (Chief Investigator (CI))
- Oh, Danielle (Primary Chief Investigator (PCI))
Project: Research